Plasma biomarkers for systemic inflammation in COVID‐19 survivors
Abstract
While the majority of COVID‐19 patients fully recover from the infection and become asymptomatic, a significant proportion of COVID‐19 survivors experience a broad spectrum of symptoms lasting weeks to months post‐infection, a phenomenon termed “post‐acute sequelae of COVID‐19 (PASC).” The aim of this study is to determine whether inflammatory proteins are dysregulated and can serve as potential biomarkers for systemic inflammation in COVID‐19 survivors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 15, 2022
- Source ID
- 10.1002/prca.202200031
Entities
People
- Benjamin J. Pelton
- Dechao Cao
- James L. Adkins
- Jinyu Zhang
- Jonathan P. Moorman
- Juan Zhao
- Lam N.t. Nguyen
- Ling Wang
- Madison Schank
- Mohamed El Gazzar
- Shunbin Ning
- Sushant Khanal
- Xiao Y. Wu
- Xindi Dang
- Yi Zhang
- Zhi Q Yao
Organizations
- American Diabetes Association
- East Tennessee State University
- National Institute of Allergy and Infectious Diseases
- National Institute on Aging
- United States Department of Defense
- United States Department of Veterans Affairs